Per S. Holm

Munich, BY 80331, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Integration of a multimeric STAT consensus site into the adenoviral genome to interfere with IFN signaling represents a novel concept to improve oncolytic virotherapy.

Integration of a multimeric STAT consensus site into the adenoviral genome to interfere with IFN signaling represents a novel concept to improve oncolytic virotherapy.

Journal: Journal of virology

Published: August 10, 2026

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

Journal: Frontiers in immunology

Published: October 31, 2023

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells.

Journal: Frontiers in oncology

Published: September 29, 2023

Intranasal Delivery of Oncolytic Adenovirus XVir-N-31 via Optimized Shuttle Cells Significantly Extends Survival of Glioblastoma-Bearing Mice.

Intranasal Delivery of Oncolytic Adenovirus XVir-N-31 via Optimized Shuttle Cells Significantly Extends Survival of Glioblastoma-Bearing Mice.

Journal: Cancers

Published: August 21, 2023

Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system.

Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system.

Journal: Molecular oncology

Published: May 30, 2023

Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.

Targeting Cell Cycle Facilitates E1A-Independent Adenoviral Replication.

Journal: Journal of virology

Published: May 23, 2023

The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.

The Oncolytic Adenovirus XVir-N-31 Joins Forces with CDK4/6 Inhibition Augmenting Innate and Adaptive Antitumor Immunity in Ewing Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 12, 2022

The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.

The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model.

Journal: International journal of molecular sciences

Published: August 04, 2022

Concepts in Oncolytic Adenovirus Therapy.

Concepts in Oncolytic Adenovirus Therapy.

Journal: International journal of molecular sciences

Published: August 27, 2021

Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.

Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.

Journal: Viruses

Published: June 02, 2021

Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.

Targeting the Retinoblastoma/E2F repressive complex by CDK4/6 inhibitors amplifies oncolytic potency of an oncolytic adenovirus.

Journal: Nature communications

Published: May 28, 2021

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.

Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer.

Journal: Journal of personalized medicine

Published: March 17, 2021

Showing 1-12 of 30

Last Updated: 09/26/2026